Quantum Menstrual Health Monitoring Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-55
SponsorQuanovate Tech Inc.
About this trial
The Quantum Menstrual Health Monitoring Study will measure four key reproductive hormones in the urine to characterize patterns that predict and confirm ovulation, referenced to serum hormones and the gold-standard of the ultrasound day of ovulation in participants with regular cycles. These normal cycles will provide a reference for comparison to irregular cycles in polycystic ovarian syndrome (PCOS) and athletes. Clinical signs in the menstrual cycle (e.g. menstrual bleeding, temperature) as well as vital sign and sleep patterns will also be referenced to hormonal changes.
Eligibility criteria
Qualifiers
Regularly menstruating, PCOS or athlete participants aged 18-45
Negative pregnancy test at the beginning and at the end of each cycle
Cycle lengths 24-34 days
Knowledge of previous 3 cycle lengths
Disqualifiers
For regular cycles
Anovulation in the last 3 cycles
Currently or in the previous 3 months, on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, etc)
Known conditions that impair ovulation or fertility: polycystic ovarian syndrome, endometriosis, pelvic inflammatory disease in the last year, pituitary adenomas, exclusively breastfeeding
Trial design
Treatments tested in this trial
- Mira Monitor tracking
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Quanovate Tech Inc.
Lead sponsor
University of British Columbia
Sponsor institution
Patricia Doyle-Baker
Collaborator
Source ClinicalTrials.gov